questionsmedicales.fr
Composés chimiques organiques
Hydrocarbures
Hydrocarbures cycliques
Hydrocarbures aromatiques
Dérivés du benzène
Phénols
Catéchols
Masoprocol
Masoprocol : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Masoprocol
Diagnostic médical
Essais cliniques
Évaluation des symptômes
Symptômes
2
Inflammation
Cancer de la peau
Effets secondaires
Irritation cutanée
Prévention
2
Prévention des maladies
Traitement
Prévention
Exposition au soleil
Traitements
2
Traitement topique
Lésions cutanées
Administration locale
Crème
Complications
2
Complications
Infections cutanées
Interactions médicamenteuses
Consultation médicale
Facteurs de risque
2
Facteurs de risque
Allergies cutanées
Immunodépression
Surveillance médicale
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Masoprocol : Questions médicales les plus fréquentes",
"headline": "Masoprocol : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Masoprocol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-01",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Masoprocol"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Catéchols",
"url": "https://questionsmedicales.fr/mesh/D002396",
"about": {
"@type": "MedicalCondition",
"name": "Catéchols",
"code": {
"@type": "MedicalCode",
"code": "D002396",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.455.426.559.389.657.166"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Masoprocol",
"alternateName": "Masoprocol",
"code": {
"@type": "MedicalCode",
"code": "D009637",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mohammed Baqur S Al-Shuhaib",
"url": "https://questionsmedicales.fr/author/Mohammed%20Baqur%20S%20Al-Shuhaib",
"affiliation": {
"@type": "Organization",
"name": "Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq."
}
},
{
"@type": "Person",
"name": "Sarfaraz Alam",
"url": "https://questionsmedicales.fr/author/Sarfaraz%20Alam",
"affiliation": {
"@type": "Organization",
"name": "Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland."
}
},
{
"@type": "Person",
"name": "Salman Ali Khan",
"url": "https://questionsmedicales.fr/author/Salman%20Ali%20Khan",
"affiliation": {
"@type": "Organization",
"name": "Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan."
}
},
{
"@type": "Person",
"name": "Hayder O Hashim",
"url": "https://questionsmedicales.fr/author/Hayder%20O%20Hashim",
"affiliation": {
"@type": "Organization",
"name": "Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq."
}
},
{
"@type": "Person",
"name": "Daniel H Obayes",
"url": "https://questionsmedicales.fr/author/Daniel%20H%20Obayes",
"affiliation": {
"@type": "Organization",
"name": "College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cholangiocarcinoma.",
"datePublished": "2024-05-10",
"url": "https://questionsmedicales.fr/article/39448128",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.suc.2024.04.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pathology of Cholangiocarcinomas.",
"datePublished": "2022-12-26",
"url": "https://questionsmedicales.fr/article/36661679",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/curroncol30010030"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immunobiology of cholangiocarcinoma.",
"datePublished": "2023-05-16",
"url": "https://questionsmedicales.fr/article/37201670",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jhep.2023.05.010"
}
},
{
"@type": "ScholarlyArticle",
"name": "FGFR2 Inhibition in Cholangiocarcinoma.",
"datePublished": "2022-09-28",
"url": "https://questionsmedicales.fr/article/36170665",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1146/annurev-med-042921-024707"
}
},
{
"@type": "ScholarlyArticle",
"name": "The multidisciplinary management of cholangiocarcinoma.",
"datePublished": "2022-11-16",
"url": "https://questionsmedicales.fr/article/36382577",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cncr.34541"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures",
"item": "https://questionsmedicales.fr/mesh/D006838"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hydrocarbures cycliques",
"item": "https://questionsmedicales.fr/mesh/D006844"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hydrocarbures aromatiques",
"item": "https://questionsmedicales.fr/mesh/D006841"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dérivés du benzène",
"item": "https://questionsmedicales.fr/mesh/D001555"
},
{
"@type": "ListItem",
"position": 7,
"name": "Phénols",
"item": "https://questionsmedicales.fr/mesh/D010636"
},
{
"@type": "ListItem",
"position": 8,
"name": "Catéchols",
"item": "https://questionsmedicales.fr/mesh/D002396"
},
{
"@type": "ListItem",
"position": 9,
"name": "Masoprocol",
"item": "https://questionsmedicales.fr/mesh/D009637"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Masoprocol - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Masoprocol",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Masoprocol",
"description": "Comment le masoprocol est-il diagnostiqué ?\nQuels tests sont utilisés pour évaluer l'efficacité du masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cholangiocarcinoma&page=1#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Masoprocol",
"description": "Quels symptômes le masoprocol peut-il traiter ?\nLe masoprocol provoque-t-il des effets secondaires ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cholangiocarcinoma&page=1#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Masoprocol",
"description": "Le masoprocol peut-il prévenir des maladies ?\nQuelles mesures préventives sont recommandées avec le masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cholangiocarcinoma&page=1#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Masoprocol",
"description": "Dans quel type de traitement le masoprocol est-il utilisé ?\nComment le masoprocol est-il administré ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cholangiocarcinoma&page=1#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Masoprocol",
"description": "Quelles complications peuvent survenir avec le masoprocol ?\nLe masoprocol peut-il interagir avec d'autres médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cholangiocarcinoma&page=1#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Masoprocol",
"description": "Qui est à risque d'effets secondaires du masoprocol ?\nY a-t-il des groupes spécifiques à surveiller avec le masoprocol ?",
"url": "https://questionsmedicales.fr/mesh/D009637?mesh_terms=Cholangiocarcinoma&page=1#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le masoprocol est-il diagnostiqué ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le masoprocol n'est pas diagnostiqué, mais utilisé dans le traitement de certaines conditions."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité du masoprocol ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests cliniques et des évaluations de symptômes sont utilisés pour mesurer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes le masoprocol peut-il traiter ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé pour traiter l'inflammation et certains types de cancers cutanés."
}
},
{
"@type": "Question",
"name": "Le masoprocol provoque-t-il des effets secondaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des irritations cutanées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le masoprocol peut-il prévenir des maladies ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'est pas utilisé pour la prévention, mais pour le traitement des maladies existantes."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives sont recommandées avec le masoprocol ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition excessive au soleil et suivre les conseils médicaux."
}
},
{
"@type": "Question",
"name": "Dans quel type de traitement le masoprocol est-il utilisé ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé dans le traitement topique des lésions cutanées et des cancers cutanés."
}
},
{
"@type": "Question",
"name": "Comment le masoprocol est-il administré ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement appliqué localement sous forme de crème ou de gel."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le masoprocol ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections cutanées peuvent survenir en cas d'irritation."
}
},
{
"@type": "Question",
"name": "Le masoprocol peut-il interagir avec d'autres médicaments ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut interagir avec certains médicaments, il est donc important de consulter un médecin."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires du masoprocol ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant une peau sensible ou des antécédents d'allergies cutanées sont à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des groupes spécifiques à surveiller avec le masoprocol ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients immunodéprimés doivent être surveillés de près lors de l'utilisation."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 26/03/2025
Contenu vérifié selon les dernières recommandations médicales
1 publication dans cette catégorie
Affiliations :
Department of Animal Production, College of Agriculture, Al-Qasim Green University, Babil, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Tunneling Group, Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
Department of Clinical Laboratory Sciences, College of Pharmacy, University of Babylon, Babil, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :
1 publication dans cette catégorie
Affiliations :
College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Publications dans "Masoprocol" :
Management of intrahepatic cholangiocarcinoma relies on a thorough understanding of the tumor's location and proximity to critical vasculobiliary structures. Mid-common bile duct tumors may require he...
Cholangiocarcinomas (CCA) are heterogeneous tumors that arise from epithelial cells of the biliary tract. They represent the second primary liver malignancy, after hepatocellular carcinoma. Recent epi...
Recent literature has significantly advanced our knowledge and understanding of the tumour immune microenvironment of cholangiocarcinoma. Detailed characterisation of the immune landscape has defined ...
Biliary tract cancer (BTC) is the second most common primary liver cancer after hepatocellular carcinoma and accounts for 2% of cancer-related deaths. BTCs are classified according to their anatomical...
Cholangiocarcinoma is a lethal malignancy of the biliary epithelium that can arise anywhere along the biliary tract. Surgical resection confers the greatest likelihood of long-term survivability. Howe...
Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have been the only trea...
Cholangiocarcinoma (CCA) is the most common primary biliary malignancy with an adverse prognosis. Although its incidence is relatively low, early diagnosis is difficult due to the lack of specific sym...
Metabolic reprogramming is a hallmark of cancer and allows tumour cells to meet the increased energy demands required for rapid proliferation, invasion, and metastasis. Indeed, many tumour cells acqui...
Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biol...
Integrative genomic analysis with functional validation uncovered biological perturbations downstream of driver events including DPCR1 , RBM47 mutations, SH3BGRL2 copy number alterations, and FGFR2 fu...
We characterized the proteogenomic landscape of 217 CCAs with 197 paired normal adjacent tissues and identified their subtypes and potential therapeutic targets. The multiomics analyses with other dat...
Lymphoepithelioma-like intrahepatic cholangiocarcinoma (LEICC) has been recently introduced as a genetically distinct of intrahepatic cholangiocarcinoma (ICC). We aimed to investigate whether LEICC ha...
Five hundred and sixty-seven consecutive patients who underwent surgical resection or liver transplantation for ICC between 2014 and 2021 were retrospectively identified. Among them, 30 patients with ...
LEICCs showed significantly higher frequencies of a non-rim arterial phase hyperenhancement (APHE), washout on post-arterial images and a smooth margin, as well as less frequencies of perilesional enh...
Compared with classical ICCs, LEICCs do have distinct radiological characteristics. A smooth margin, non-rim APHE, washout on post-arterial images, absent perilesional enhancement and absent liver cap...